Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | KDM4A | O75164 | 1/20 | 0.44 |
| ▸ | KDM4B | O94953 | 1/20 | 0.44 |
| ▸ | KDM5C | P41229 | 1/20 | 0.44 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.44 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.44 |
| ▸ | KDM3A | Q9Y4C1 | 1/20 | 0.44 |
| ▸ | AXL | P30530 | 1/20 | 0.44 |
| ▸ | PRKCI | P41743 | 1/20 | 0.44 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.37 |
| ▸ | DAO | P14920 | 1/20 | 0.37 |
| ▸ | NFATC1 | O95644 | 2/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.37 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
| ▸ | CHUK | O15111 | 2/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | LATS1 | O95835 | 4/20 | 0.36 |
| ▸ | LATS2 | Q9NRM7 | 1/20 | 0.36 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8461 | 0.83 | GAA (0.45) | GAAAXLPRKCIDAONFATC1 | |
| SCHEMBL29397640 | 0.74 | KDM4E (0.48) | KDM4AKDM4BKDM5CKDM4CKDM5B | |
| SCHEMBL276512 | 0.74 | KDM4C (0.48) | KDM4AKDM4BKDM5CKDM4CKDM5B | |
| SCHEMBL30509527 | 0.74 | AXL (0.47) | KDM4AKDM4BKDM5CKDM4CKDM5B | |
| SCHEMBL8277148 | 0.74 | CCR1 (0.46) | KDM4AKDM4BKDM5CKDM4CKDM5B | |
| SCHEMBL18574398 | 0.74 | KDM4C (0.44) | KDM4AKDM4BKDM5CKDM4CKDM5B | |
| SCHEMBL2014072 | 0.74 | KDM4C (0.44) | KDM4AKDM4BKDM5CKDM4CKDM5B | |
| SCHEMBL20726690 | 0.74 | KDM4C (0.44) | KDM4AKDM4BKDM5CKDM4CKDM5B | |
| SCHEMBL21917159 | 0.74 | AXL (0.47) | KDM4AKDM4BKDM5CKDM4CKDM5B | |
| SCHEMBL276513 | 0.74 | KDM4E (0.48) | KDM4AKDM4BKDM5CKDM4CKDM5B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250360145-A1 | CSF-1R INHIBITORS AND USES THEREOF | MYROBALAN THERAPEUTICS INC (US) | 2025-11-27 | — | — | US | disclosed |
| US-20250320204-A1 | 7-AZA BICYCLIC HETEROARYL DERIVATIVES AS ECTONUCLEOTIDE PYROPHOSPHATASE PHOSPHODIESTERASE 1 INHIBITORS | RIBOSCIENCE LLC (US) | 2025-10-16 | — | — | US | disclosed |
| US-12371428-B2 | Pyridone compounds and methods of use | EXELIXIS, INC. (US) | 2025-07-29 | — | — | US | disclosed |
| WO-2025094035-A1 | TOLL-LIKE RECEPTOR AGONISTS AND CONJUGATES THEREOF | PFIZER INC. (US) | 2025-05-08 | — | — | WO | disclosed |
| EP-4539933-A1 | CSF-1R INHIBITORS AND USES THEREOF | Myrobalan Therapeutics, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| CN-119790038-A | CSF-1R inhibitors and uses thereof | 迈巴制药公司 | 2025-04-08 | — | — | CN | disclosed |
| US-20240025898-A1 | HPK1 ANTAGONISTS AND USES THEREOF | SCHRÖDINGER, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20240025898-A1 | HPK1 ANTAGONISTS AND USES THEREOF | SCHRÖDINGER, INC. | 2024-01-25 | — | — | US | disclosed |
| WO-2023241608-A1 | CSF-1R INHIBITORS AND USES THEREOF | MYROBALAN THERAPEUTICS NANJING CO. LTD (CN) | 2023-12-21 | — | — | WO | disclosed |
| WO-2023225001-A1 | NAPHTHYRIDINE BASED ENPP1 MODULATORS AND USES THEREOF | Vir Biotechnology, Inc. (US) | 2023-11-23 | — | — | WO | disclosed |
| US-20130102603-A1 | 2,4-DIARYL - SUBSTITUTED [1,8] NAPHTHYRIDINES AS KINASE INHIBITORS FOR USE AGAINST CANCER | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-04-25 | — | — | US | disclosed |
| CN-102958930-A | 2,4- diaryl - substituted [1,8] naphthyridines as kinase inhibitors for use against cancer | MERCK PATENT GMBH | 2013-03-06 | — | — | CN | disclosed |
| EP-2499129-A1 | QUINOLINE AND QUINOXALINE DERIVATIVES AS KINASE INHIBITORS | UCB Pharma, S.A. (BE) | 2012-09-19 | — | — | EP | disclosed |
| WO-2012000595-A1 | 2,4- DIARYL - SUBSTITUTED [1,8] NAPHTHYRIDINES AS KINASE INHIBITORS FOR USE AGAINST CANCER | MERCK PATENT GMBH (DE) | 2012-01-05 | — | — | WO | disclosed |
| WO-2012000595-A1 | 2,4- DIARYL - SUBSTITUTED [1,8] NAPHTHYRIDINES AS KINASE INHIBITORS FOR USE AGAINST CANCER | MERCK PATENT GMBH (DE) | 2012-01-05 | — | — | WO | disclosed |
| WO-2011058108-A1 | QUINOLINE AND QUINOXALINE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2011-05-19 | — | — | WO | disclosed |
| EP-2139332-A1 | SUBSTITUTED PYRIDO[2,3-D]PYRIMIDINE DERIVATIVES AS CANNABINOID-1 RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2010-01-06 | — | — | EP | disclosed |
| WO-2008121257-A1 | SUBSTITUTED PYRIDO[2,3-D]PYRIMIDINE DERIVATIVES AS CANNABINOID-1 RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2008-10-09 | — | — | WO | disclosed |
| WO-2008077650-A1 | PYRIDO(3,2-D)PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2008-07-03 | — | — | WO | disclosed |
| WO-2007113548-A1 | NAPHTHYRIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2007-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12371428-B2 | Pyridone compounds and methods of use | PDXK, PLK2, MAP4K2 | GAA 2746/4885KDM4A 3656/4885KDM4B 3588/4885 |
| US-20250320204-A1 | 7-AZA BICYCLIC HETEROARYL DERIVATIVES AS ECTONUCLEOTIDE PYROPHOSPHATASE PHOSPHODIESTERASE 1 INHIBITORS | ENPP1, ENPP3, PDE7A | GAA 188/4885KDM4A 2120/4885KDM4B 1960/4885 |
| US-20240025898-A1 | HPK1 ANTAGONISTS AND USES THEREOF | PDXK, HIPK1, PCK1 | GAA 905/4885KDM4A 3090/4885KDM4B 3838/4885 |
| US-20250360145-A1 | CSF-1R INHIBITORS AND USES THEREOF | CSF1R, CSF3R, IL1RN | GAA 720/4885KDM4A 4156/4885KDM4B 4218/4885 |
| US-20130102603-A1 | 2,4-DIARYL - SUBSTITUTED [1,8] NAPHTHYRIDINES AS KINASE INHIBITORS FOR USE AGAINST CANCER | TGFBR1, TAB1, TGFBR2 | GAA 2059/4885KDM4A 1804/4885KDM4B 1867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.